The table below summarizes the significant expense categories regularly provided to the CODM for the three months ended March 31, 2026 and 2025: | | | | | | | | | | | | | Three Months Ended | | | | | | | March 31, | | | (in thousands) | | 2026 | | 2025 | | | Operating expenses: | | | | | | | | | Research and development: Firmonertinib (excluding personnel-related and other internal costs): | | | | | | | | | FURTHER | | $ | 1,738 | | $ | 2,595 | | | FURVENT | | | 9,131 | | | 9,445 | | | FAVOUR | | | 331 | | | 2 | | | Other Firmonertinib costs | | | 3,883 | | | 2,262 | | | Total Firmonertinib | | | 15,083 | | | 14,304 | | | Research and development: Early-stage programs | | | 12,307 | | | 40,981 | | | Research and development: Personnel-related and other internal costs | | | 10,227 | | | 6,005 | | | General and administrative: Personnel-related costs | | | 6,183 | | | 3,331 | | | General and administrative: Other costs | | | 2,311 | | | 2,151 | | | Other segment items (a) | | | (2,791) | | | (2,385) | | | Net loss | | $ | 43,320 | | $ | 64,387 | | |
(a) Other segment items consists of interest and investment income.
|